At this stage, endpoints and sample size are not statistically driven; however, study results may be useful in designing the pivotal study, in particular for endpoint selection and assumptions used in power calculation. this website A sample size of 20 implanted patients was considered clinically sufficient by the U.S. Food and Drug Administration to provide preliminary data on both safety and potential efficacy. Absolute changes in efficacy measures from baseline to follow-up were included in the statistical plan. An independent

Data and Safety Monitoring Board (see the Online Appendix) monitored safety. SAS statistical software (release 9.3 TS1M3, SAS Institute, Cary, North Carolina) was used. The safety of the C-Pulse System was evaluated by reviewing a composite of the device-related adverse events through 6 months, as adjudicated by the Clinical Events Committee. The composite device-related adverse event rate included death, major infection, aortic disruption, neurological dysfunction, myocardial infarction, or any other device-related adverse event. Safety was defined as

the composite device-related adverse event rate and reported with its 95% 2-sided exact confidence interval. The composite device-related adverse event rate is assumed to follow the binomial distribution and defined as the percent of patients who experience at least 1 of the primary adverse events. All patients are included in reporting of safety. Baseline and follow-up data were used to assess differences in NYHA functional class, QoL, and exercise variables VE-822 research buy before and after implant. The statistical analysis used data from paired samples. Only those patients providing paired assessments were included in the efficacy analyses. The mean point estimates and their respective standard deviations are presented for NYHA functional class, QoL scores, 6MWD,

and pVO2. Comparison of paired data was performed using mean difference, standard deviation, and Wilcoxon signed rank test p value for each variable. A nominal p value of <0.05 was considered statistically significant. No adjustment was made for multiple comparisons. Between April 15, 2009 and June 20, 2011, 32 patients were screened for study inclusion; 20 were confirmed eligible and implanted ADP ribosylation factor and 12 were considered as screen failures. Reasons for exclusion included ascending aortic disease or nonconforming dimensions (n = 3), decreased functional capacity (6MWD and/or pV02 below criteria, n = 2), withdrawal of consent or were withdrawn by the investigator (n = 5), left ventricular ejection fraction >35% (n = 1), and recent stroke (n = 1). The characteristics of study participants are presented in Table 1. As required by protocol, all patients were on stable optimal medical therapy. All had an implantable cardioverter-defibrillator, and 45% had a combined biventricular pacer–implantable cardioverter-defibrillator.